Personalized Cancer Vaccine Shows Durable Benefit at 5 Years

Cancer Discovery 2026

View at publisher
DOI: 10.1158/2159-8290.cd-nw2026-0009
Cited by: 0

Abstract

Five-year data from the phase IIb KEYNOTE-942 study show that the mRNA-based neoantigen vaccine intismeran autogene continues to reduce the risk of melanoma recurrence or death by roughly 49% when combined with pembrolizumab. This durability strengthens confidence in the personalized vaccine strategy, but a larger phase III trial will provide the decisive findings.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Cutaneous Melanoma Detection and Management

Publication details

Journal / source
Cancer Discovery
Volume
16
Issue
3
Pages
OF1–OF1
Publication date
2 February 2026
Language
EN